Daily Endocrinology Research Analysis
Three high-impact endocrine studies stood out today: a 52-week phase 3 RCT showing elinzanetant reduces menopausal vasomotor symptoms with a favorable safety profile; a multicenter RCT demonstrating that myo-inositol does not prevent major pregnancy complications in women with PCOS; and a PRISMA-compliant meta-analysis of RCTs showing automated insulin delivery improves HbA1c, time in range, and nocturnal control in youth with type 1 diabetes without increasing adverse events.
Summary
Three high-impact endocrine studies stood out today: a 52-week phase 3 RCT showing elinzanetant reduces menopausal vasomotor symptoms with a favorable safety profile; a multicenter RCT demonstrating that myo-inositol does not prevent major pregnancy complications in women with PCOS; and a PRISMA-compliant meta-analysis of RCTs showing automated insulin delivery improves HbA1c, time in range, and nocturnal control in youth with type 1 diabetes without increasing adverse events.
Research Themes
- Non-hormonal therapies for menopausal vasomotor symptoms
- Perinatal risk modification in PCOS pregnancies
- Diabetes technology and glycemic outcomes in youth
Selected Articles
1. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
In OASIS-3 (n=628), once-daily elinzanetant 120 mg reduced daily moderate-to-severe vasomotor symptom frequency more than placebo at week 12 (LS mean difference −1.6; 95% CI, −2.0 to −1.1; P<.001) and showed numerical benefits through 50–52 weeks on VMS severity, sleep, and menopause-related quality of life. Safety signals did not include hepatotoxicity, endometrial hyperplasia, or meaningful bone effects; treatment-related adverse events (somnolence, fatigue, headache) were more frequent with elinzanetant.
Impact: This large, long-duration phase 3 RCT provides robust evidence for a non-hormonal, neurokinin-targeted therapy for menopausal VMS with a reassuring safety profile.
Clinical Implications: Elinzanetant may be considered for moderate-to-severe menopausal vasomotor symptoms in women who prefer or require non-hormonal therapy, with monitoring for somnolence and fatigue.
Key Findings
- At week 12, elinzanetant reduced daily moderate-to-severe VMS frequency vs placebo (LS mean difference −1.6; 95% CI, −2.0 to −1.1; P<.001).
- Numerical improvements in VMS frequency/severity (to 50 weeks), sleep disturbance, and menopause-related quality of life (to 52 weeks).
- No hepatotoxicity, endometrial hyperplasia, or clinically meaningful bone effects; higher treatment-related adverse events (30.4% vs 14.6%), mainly somnolence, fatigue, headache.
Methodological Strengths
- Double-blind, placebo-controlled, randomized phase 3 design across 83 sites with 52-week follow-up.
- Pre-specified primary endpoint analyzed with mixed model for repeated measures and registered trial (NCT05030584).
Limitations
- Secondary and exploratory endpoints were not powered for between-group comparisons and lacked formal hypothesis testing.
- Generalizability may be limited by trial inclusion criteria and demographics; adverse events were more frequent with active treatment.
Future Directions: Head-to-head comparisons with hormonal therapies, dose-optimization, diverse populations, and mechanistic studies on neurokinin blockade and sleep/circadian outcomes.
IMPORTANCE: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances. OBJECTIVE: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause. DESIGN, SETTING, AND PARTICIPANTS: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week). The data were analyzed on March 11, 2024.
2. Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
In 464 pregnant individuals with PCOS randomized to myo-inositol (2 g + 0.2 mg folic acid twice daily) vs placebo (folic acid only), the primary composite (gestational diabetes, preeclampsia, preterm birth) occurred in 25.0% vs 26.8% (RR 0.93; 95% CI, 0.68–1.28; P=.67). Myo-inositol did not reduce the incidence of adverse pregnancy outcomes.
Impact: This well-powered multicenter RCT provides definitive negative evidence against routine myo-inositol use to prevent major pregnancy complications in PCOS, informing practice and guideline updates.
Clinical Implications: Routine myo-inositol supplementation during pregnancy in PCOS should not be recommended for preventing gestational diabetes, preeclampsia, or preterm birth; focus should remain on established risk management strategies.
Key Findings
- Primary composite outcome occurred in 25.0% (myo-inositol) vs 26.8% (placebo); RR 0.93 (95% CI, 0.68–1.28; P=.67).
- Participants received 2 g myo-inositol + 0.2 mg folic acid twice daily vs matched placebo from 8–16 weeks’ gestation until delivery.
- Baseline biochemical hyperandrogenism was more prevalent in the myo-inositol group (29.0% vs 18.5%).
Methodological Strengths
- Double-blind, placebo-controlled, randomized multicenter design with clear composite clinical endpoint.
- Prospective protocol and trial registration with intention-to-treat analysis.
Limitations
- Baseline imbalance in biochemical hyperandrogenism may confound subgroup effects.
- Conducted in the Netherlands; generalizability to broader, more diverse populations is uncertain; adherence and secondary outcomes are not detailed in the abstract.
Future Directions: Explore targeted subgroups (e.g., by insulin resistance or hyperandrogenism), dosing/timing strategies, and alternative interventions to prevent PCOS-related obstetric complications.
IMPORTANCE: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks. OBJECTIVE: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, randomized trial was conducted at 13 hospitals in the Netherlands.
3. Automated Insulin Delivery Systems and Glucose Management in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis.
Across 11 RCTs (n=901 for HbA1c; 10 RCTs n=786 for TIR), AID reduced HbA1c by −0.41% (95% CI, −0.58 to −0.25; I2=39%) and increased time in range by 11.5% (95% CI, 9.3%–13.7%; I2=23%), with larger nighttime benefits (TIR +19.7%). Time in hyperglycemia decreased (−10.8% overall; −14.4% at night) and time in hypoglycemia modestly decreased (−0.32%). Adverse events were similar between arms; QOL data were sparse.
Impact: This PRISMA-compliant meta-analysis of outpatient RCTs consolidates efficacy and safety of AID in youth, quantifying meaningful improvements in HbA1c, TIR, and nocturnal control—key for pediatric diabetes care decisions.
Clinical Implications: Supports broader adoption of AID systems in children and adolescents with T1D to improve glycemic metrics, particularly nocturnal control, with attention to patient-reported outcomes in future implementations.
Key Findings
- HbA1c decreased by −0.41% (95% CI, −0.58 to −0.25; I2=39%) with AID vs comparators.
- Time in range increased by 11.5% (95% CI, 9.3%–13.7%; I2=23%); nighttime TIR increased by 19.7%.
- Time in hyperglycemia decreased by −10.8% (night −14.4%); time in hypoglycemia decreased by −0.32%; adverse events did not differ between arms.
Methodological Strengths
- PRISMA-compliant systematic review with independent screening, data extraction, and risk-of-bias assessment.
- Random-effects models with heterogeneity reporting; outpatient RCTs and objective CGM-derived endpoints.
Limitations
- Quality-of-life outcomes were reported in only 2 studies, limiting patient-centered conclusions.
- Intervention durations varied (mean 31 weeks, SD 26), and heterogeneity was moderate for some outcomes.
Future Directions: Longer-term RCTs assessing durability, psychosocial outcomes, real-world adherence, and cost-effectiveness; subgroup analyses by age, baseline HbA1c, and hypoglycemia risk.
IMPORTANCE: Youth living with type 1 diabetes (T1D) are increasingly choosing automated insulin delivery (AID) systems to manage their blood glucose. Few systematic reviews meta-analyzing results from randomized clinical trials (RCTs) are available to guide decision-making. OBJECTIVE: To study the association of prolonged AID system use in an outpatient setting with measures of glucose management and quality of life in youth with T1D. DATA SOURCES: MEDLINE, Embase, CINAHL, and Cochrane Central were searched from January 2017 to March 2025 to identify eligible RCTs.